drugset / Trial / NCT02123316

Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis

NCT02123316 ↗

Phase 2 Completed 36 enrolled Miguel Blanca Gomez
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of an extract of Dermatophagoides pteronyssinus versus placebo in the treatment of local allergic rhinitis. The primary efficacy endpoint is the reduction in symptom scores and medication use in the active group compared to placebo. The influence of treatment in "in vitro" and "in vivo" objective parameters was also assessed.

Timeline

Start
2010-01
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pangramin Plus D. pteronyssinus Other / unclassified — Subcutaneous

Indications